The development of the therapy for metastatic pancreatic cancer targeting its microenvironment.

• Project/Area Number: 25670591
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Digestive surgery
• Research Institution: Miyagi Prefectural Hospital Organization Miyagi Cancer Center
• Principal Investigator: YAMANAMI Hideaki 地方独立行政法人宮城県立病院機構宮城県立がんセンター(研究所), がん幹細胞研究部, 共同研究員 (70270840)
• Co-Investigator(Kenkyū-buntansha): SATOH Kennichi 地方独立行政法人宮城県立病院機構宮城県立がんセンター(研究所), がん幹細胞研究部, 部長 (10282055)
• Project Period (FY): 2013-04-01 – 2015-03-31
• Project Status: Completed (Fiscal Year 2014)
• Budget Amount: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000); Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000); Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
• Keywords: 膵癌 / 微小環境 / ペリオスチン / Periostin

Outline of Final Research Achievements

Cancer stroma (microenvironment) is shown to be involved in pancreatic cancer development. Periostin, which is expressed in stroma, is suggested to be an important molecule related to pancreatic cancer progression. To assess the possibility of development of the effective therapy for pancreatic cancer by targeting Periosin, we compared the pancreatic tissues derived from Pdx1-cre; K-ras G12D; Periostin+/+ with Pdx1-cre; K-ras G12D; Periostin-/- mice. PanIN formation was delayed in Periostin-/- compared to Periostin+/+ mice, suggesting that Periostin is involved in pancreatic carcinogenesis and might be therapeutic target.

Research Products

• [Journal Article] MiR-365 induces gemcitabine resistance in pancreatic cancer cells by targeting the adaptor protein SHC1 and pro-apoptotic regulator BAX (2014)
  • Author(s): Hamada S, Masamune A, Miura S, Satoh K, Shimosegawa T
  • Journal Title: Cell Signal Volume: 26(2) Issue: 2 Pages: 179-185
  • DOI: 10.1016/j.cellsig.2013.11.003
  • Peer Reviewed
• [Journal Article] Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer. (2014)
  • Author(s): Abue, M., Yokoyama, M., Shibuya, R., Tamai, K., Yamaguchi, K., Sato, I., Tanaka, N., Hamada, S., Shimosegawa, T., Sugamura, K., Satoh, K.
  • Journal Title: Int J Oncol Volume: 10 Issue: 2 Pages: 1-9
  • DOI: 10.3892/ijo.2014.2743
  • Peer Reviewed / Open Access / Acknowledgement Compliant